Literature DB >> 25023994

The potential risks of expedited approval of drugs for acute bacterial infections.

James S Floyd1, Bruce M Psaty2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25023994      PMCID： PMC4232183          DOI： 10.1001/jamainternmed.2014.3055

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  5 in total

1.  Accelerated approval and possible withdrawal of midodrine.

Authors:  Sanket S Dhruva; Rita F Redberg
Journal:  JAMA       Date:  2010-11-17       Impact factor: 56.272

Review 2.  Surrogate end points in clinical trials: are we being misled?

Authors:  T R Fleming; D L DeMets
Journal:  Ann Intern Med       Date:  1996-10-01       Impact factor: 25.391

3.  Why does antimicrobial overuse in hospitalized patients persist?

Authors:  Scott A Flanders; Sanjay Saint
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

Review 4.  Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.

Authors:  George H Talbot; John H Powers; Thomas R Fleming; Judith A Siuciak; John Bradley; Helen Boucher
Journal:  Clin Infect Dis       Date:  2012-06-28       Impact factor: 9.079

5.  Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.

Authors:  Emanuele Durante-Mangoni; Giuseppe Signoriello; Roberto Andini; Annunziata Mattei; Maria De Cristoforo; Patrizia Murino; Matteo Bassetti; Paolo Malacarne; Nicola Petrosillo; Nicola Galdieri; Paola Mocavero; Antonio Corcione; Claudio Viscoli; Raffaele Zarrilli; Ciro Gallo; Riccardo Utili
Journal:  Clin Infect Dis       Date:  2013-04-24       Impact factor: 9.079
  5 in total
  1 in total

1.  Accelerating innovation in rapid diagnostics and targeted antibacterials.

Authors:  Thomas J Hwang; John H Powers; Daniel Carpenter; Aaron S Kesselheim
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.